Geert Mayer
Overview
Explore the profile of Geert Mayer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
3096
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Winter Y, Mayer G, Kotterba S, Benes H, Burghaus L, Koch A, et al.
Sleep Med
. 2023 Feb;
103:138-143.
PMID: 36796288
Background: Excessive daytime sleepiness (EDS) is a core narcolepsy symptom, for which solriamfetol (Sunosi®) was recently approved in the European Union. SURWEY characterises real-world strategies used by physicians when initiating...
12.
Cesari M, Heidbreder A, St Louis E, Sixel-Doring F, Bliwise D, Baldelli L, et al.
Sleep
. 2022 Dec;
46(1).
PMID: 36519899
No abstract available.
13.
Mayer G, Gronewold J, Hermann D, Polidori-Nelles M, Frohnhofen H
MMW Fortschr Med
. 2022 Dec;
164(21-22):48-50.
PMID: 36510072
No abstract available.
14.
Janzen A, Vadasz D, Booij J, Luster M, Librizzi D, Henrich M, et al.
J Parkinsons Dis
. 2022 Jun;
12(6):1921-1935.
PMID: 35754288
Background: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Objective: We investigated the use of cardiac [123I]meta-iodo-benzyl-guanidine scintigraphy...
15.
16.
Zhang Z, Dauvilliers Y, Plazzi G, Mayer G, Lammers G, Santamaria J, et al.
Nat Sci Sleep
. 2022 Jun;
14:1031-1047.
PMID: 35669411
Purpose: Narcolepsy type-1 (NT1) is a rare chronic neurological sleep disorder with excessive daytime sleepiness (EDS) as usual first and cataplexy as pathognomonic symptom. Shortening the NT1 diagnostic delay is...
17.
Gool J, Zhang Z, Oei M, Mathias S, Dauvilliers Y, Mayer G, et al.
Neurology
. 2022 Apr;
98(23):e2387-e2400.
PMID: 35437263
Background And Objectives: Recent studies fueled doubts as to whether all currently defined central disorders of hypersomnolence are stable entities, especially narcolepsy type 2 and idiopathic hypersomnia. New reliable biomarkers...
18.
Janzen A, Kogan R, Meles S, Sittig E, Renken R, Geibl F, et al.
Mov Disord
. 2021 Nov;
37(3):624-629.
PMID: 34796976
Background: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for α-synucleinopathies. Objective: The aim of this study was to determine whether pathological cardiac [ I]meta-iodobenzylguanidine scintigraphy ([ I]MIBG)...
19.
Cesari M, Heidbreder A, St Louis E, Sixel-Doring F, Bliwise D, Baldelli L, et al.
Sleep
. 2021 Oct;
45(3).
PMID: 34694408
Video-polysomnography (v-PSG) is essential for diagnosing rapid eye movement (REM) sleep behavior disorder (RBD). Although there are current American Academy of Sleep Medicine standards to diagnose RBD, several aspects need...
20.
Weaver T, Pepin J, Schwab R, Shapiro C, Hedner J, Ahmed M, et al.
J Clin Sleep Med
. 2021 Oct;
17(10):1995-2007.
PMID: 34606437
Study Objectives: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the United States and European Union for excessive daytime sleepiness in adults with narcolepsy (75-150 mg/day) or obstructive sleep apnea...